Effect of irbesartan and enalapril in non-ST elevation acute coronary syndrome: results of the randomized, double-blind ARCHIPELAGO study
Open Access
- 21 August 2009
- journal article
- research article
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 30 (22) , 2733-2741
Abstract
This study investigated the effects of irbesartan vs. enalapril, with early vs. late treatment, on markers of inflammation and ischaemic heart disease in patients with non-ST-segment elevation acute coronary syndrome (NSTEACS). Patients hospitalized with ischaemic symptoms and evidence of NSTEACS were randomized to early (at hospitalization) or late (at hospital discharge) treatment with irbesartan 150 mg/day followed by 300 mg/day on day 15 (n = 212) or enalapril 10 mg/day followed by 20 mg/day on day 15 (n = 217) to day 60. The primary endpoint was the change from baseline in high-sensitivity C-reactive protein (hs-C-reactive protein) at day 60; secondary endpoints included changes in troponin I, B-type natriuretic peptide, microalbuminuria, interleukin 6, myeloperoxidase, secretory non-pancreatic type II phospholipase A2, ischaemia-modified albumin, soluble CD40 ligand, matrix metalloproteinase-9, aldosterone, and blood pressure. High-sensitivity C-reactive protein levels were comparable in both the irbesartan and enalapril treatment arms. There were no treatment-related differences in any of the biomarkers measured. Changes in inflammatory markers were unaffected by the timing of treatment initiation. Both treatments were well tolerated, with no differences in major adverse cardiac events. In patients with NSTEACS, inflammatory markers decreased over time in both treatment arms, with no differences between irbesartan and enalapril.Keywords
This publication has 46 references indexed in Scilit:
- A review of high-dose statin therapy: targeting cholesterol and inflammation in atherosclerosisEuropean Heart Journal, 2007
- High Plasma Aldosterone Levels on Admission Are Associated With Death in Patients Presenting With Acute ST-Elevation Myocardial InfarctionCirculation, 2006
- Angiotensin II and inflammation: the effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockadeJournal of Human Hypertension, 2006
- Effects of early angiotensin-converting enzyme inhibition in patients with non–ST-elevation acute anterior myocardial infarctionAmerican Heart Journal, 2006
- Irbesartan significantly reduces C reactive protein concentrations after 1 month of treatment in unstable anginaHeart, 2005
- Irbesartan and Lipoic Acid Improve Endothelial Function and Reduce Markers of Inflammation in the Metabolic SyndromeCirculation, 2005
- Evaluation of B-type natriuretic peptide for risk assessment in unstable Angina/Non–ST-elevation myocardial infarctionJACC, 2003
- C-Reactive Protein and Other Inflammatory Biomarkers as Predictors of Outcome Following Acute Coronary SyndromesSeminars in Vascular Medicine, 2003
- Short-term effects of atorvastatin on C-reactive proteinEuropean Heart Journal, 2002
- Microalbuminuria during acute myocardial infarction; a strong predictor for 1-year mortalityEuropean Heart Journal, 2001